Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
October 6, 2026
Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz
September 15, 2022
Related Post
-
-
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
October 1, 2026
-
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
September 29, 2026
-
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
September 22, 2026